arrow
L

Lin Shen

department of biology and medicine
H指数:26
被引数:2,717

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+advanced, unresectable or metastatic G/GEJ adenocarcinoma

KEYNOTE-811研究的III期最终总生存数据,该研究评估了帕博利珠单抗联合曲妥珠单抗和化疗治疗HER2阳性、不可切除或转移性胃/胃食管结合部腺癌。

2024-12-010
PRE
An open-label, MRCT phase I/II study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of first-in-class bi-ligand-drug conjugate CBP-1019 in patients (pts) with advanced solid tumors

一项开放标签、多区域协作临床试验(MRCT)I/II期研究,旨在评估第一类双配体药物偶联物CBP-1019在晚期实体瘤患者(pts)中的安全性、耐受性、药代动力学及初步疗效。

2024-09-010
PRE
Preliminary result of a phase Ib study: Efficacy and safety of FG-M108 plus gemcitabine and nab-paclitaxel in patients with Claudin18.2 positive locally advanced unresectable or metastaticpancreatic cancer

Ib期研究的初步结果:FG-M108联合吉西他滨和nab-紫杉醇在Claudin18.2阳性局部晚期不可切除或转移性胰腺癌患者中的有效性和安全性

2024-09-010
PRE
SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study

基于SALIRI的 (雷替曲塞联合伊立替康) 疗法作为转移性结直肠癌患者的二线治疗 (SALLY): 一项前瞻性,多中心,非干预性,注册研究

2024-07-080
OAAI
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial

Zolbetuximab联合CAPOX治疗CLDN18.2阳性胃或胃食管交界处腺癌: 随机,3期GLOW试验

2023-07-31158
OAAI
A multicenter Phase II study of savolitinib in patients with MET-amplified gastroesophogeal junction adenocarcinomas or gastric cancer
2023-04-141
PRE